Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
Talia Golan, Tal Grenader, Patricia Ohana, Yasmine Amitay, Hilary Shmeeda, Ninh M La-Beck, Esther Tahover, Raanan Berger, Alberto A Gabizon, Talia Golan, Tal Grenader, Patricia Ohana, Yasmine Amitay, Hilary Shmeeda, Ninh M La-Beck, Esther Tahover, Raanan Berger, Alberto A Gabizon
Abstract
Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use. In animals, pegylated liposomal mitomycin C lipid-based prodrug (PL-MLP) was well tolerated and more effective than free MMC. We evaluated PL-MLP in patients with advanced cancer. Twenty-seven patients were treated in escalating dose cohorts of 0.5-3.5 mg/kg (equivalent to 0.15-1.03 mg/kg MMC) every 4 weeks for up to 12 cycles, unless disease progression or unacceptable toxicity occurred. Pharmacokinetics were assessed during cycles 1 and 3. Per protocol maximum tolerated dose was not reached at 3.5 mg/kg. However, prolonged thrombocytopenia developed after repeated doses of 3 mg/kg or cumulative doses of 10-12 mg/kg. Dose-related grade 3 or higher adverse events included fatigue, anemia, and decreased platelets. Cmax and AUC0-∞ increased linearly over the dose range 0.5-2.0 mg/kg, and greater than linearly from 2.5 to 3.5 mg/kg; there were no significant differences in clearance of MLP between cycles 1 and 3. Median t1/2 was 23 h among dose cohorts, with no trend by dose or cycle. One patient had a partial response. Stable disease was observed in 10 patients across all dose levels. PL-MLP has a long circulation time, was well tolerated, and can be administered to heavily pretreated patients at a single dose of 3.0 mg/kg and cumulative dose of 10-12 mg/kg before development of prolonged thrombocytopenia; this is nearly threefold the equivalent dose of MMC tolerated historically. This formulation may be active in a variety of tumor types and is better tolerated than free MMC.
Trial registration: ClinicalTrials.gov NCT01705002.
Keywords: Clinical trial; liposome; mitomycin C; prodrug.
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Figures
References
- Crooke ST. Bradner WT. Mitomycin C: a review. Cancer Treat. Rev. 1976;3:121–139.
- Verweij J. Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs. 1990;1:5–13.
- Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ, et al. Mitomycin C: a prototype bioreductive agent. Oncol. Res. 1994;6:501–508.
- Tomasz M. Mitomycin C: small fast and deadly (but very selective) Chem. Biol. 1995;2:575–579.
- James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–524.
- Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JR, Pierre KM, et al. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin. Cancer Res. 1997;3:1339–1346.
- Maitra R, Halpin PA, Karlson KH, Page RL, Paik DY, Leavitt MO, et al. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem J. 2001;355:617–624.
- Gabizon A, Shmeeda H. Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur. J. Pharm. Sci. 2012;45:388–398.
- Lyseng-Williamson KA, Duggan ST. Keating GM. Pegylated liposomal doxorubicin: a guide to its use in various malignancies. BioDrugs. 2013;27:533–540.
- Bertrand N, Wu J, Xu X, Kamaly N. Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014;66:2–25.
- Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J. Zalipsky S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin. Cancer Res. 2006;12:1913–1920.
- Powis G. Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 2007;7:392–397.
- Stern ST, Hall JB, Yu LL, Wood LJ, Paciotti GF, Tarmarkin L, et al. Translational considerations for cancer nanomedicine. J. Controlled Release. 2010;146:164–174.
- Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H. Zalipsky S. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. J. Controlled Release. 2012;160:245–253.
- Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions. Ann. Oncol. 2003;14:1430–1437.
- Zalipsky S, Saad M, Kiwan R, Ber E, Yu N. Minko T. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action. J. Drug Target. 2007;15:518–530.
- Szebeni J, Muggia F, Gabizon A. Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011;63:1020–1030.
- Buyon JP, Tamerius J, Belmont HM. Abramson S. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum. 1992;35:1028–1037.
- Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br. J. Cancer. 2005;93:510–514.
- Verweij J, van der Burg MEL. Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother. Oncol. 1987;8:33–41.
- Arnér ES. Holmgren A. The thioredoxin system in cancer. Semin. Cancer Biol. 2006;16:420–426.
- Dennis IF, Ramsay JR, Workman P. Bleehen NM. Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer. Cancer Chemother. Pharmacol. 1993;32:67–72.
- Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H. Sapir R. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother. Pharmacol. 2008;61:695–702.
Source: PubMed